Randomized, open-label study to compare the effect of the compounds of inhaled corticosteroid and long-acting beta2 agonist on pulmonary function and symptomatic control in association with inspiratory flow in elderly patients with bronchial asthma.
Not Applicable
- Conditions
- bronchial asthma
- Registration Number
- JPRN-UMIN000008530
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Not provided
Exclusion Criteria
1. Contraindication to budesonide/formoterol or fluticasone /salmeterol compound. 2. High-dose ICS/LABA have already been prescribed (Symbicot(R) inhalation>=6 times/day or Adair(R) 500 inhalation). 3. Respiratory infection in last 4 weeks before enrollment. 4. Beta2 agonist in any form. 5. Systemic corticosteroid therapy in last 30 days before enrollment. 6. Any serious comorbidity. 7. Being or willing to be pregnant 8. Investigator judged as inappropriate for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference of %FEV1.0 before and after the therapy for eight weeks.
- Secondary Outcome Measures
Name Time Method Difference in Inspiratory flow and ACQ (Asthma Control Questionnaire) before and after the therapy for eight weeks.